Abstract:We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical hexahydrocannabinol template (monofunctionalized probes). Such groups include the electrophilic isothiocyanato, the photoactivatable azido, and the polar cyano moieties. These groups can also be combined to produce bifunctionalized probes potentially capable of interacting at two distinct sites within the CBR-binding domains. These novel compounds display remarkably high binding affinities for CBRs and are exceptionally potent agonists. A key ligand (27a, AM11245) exhibits exceptionally high potency in both in vitro and in vivo assays and was designated as "megagonist," a property attributed to its tight binding profile. By acting both centrally and peripherally, 27a distinguishes itself from our previously reported "megagonist" AM841, whose functions are restricted to the periphery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02053?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02053</a>.Experimental procedures, spectroscopic, analytical, and physical data for 12a–b, 13a–b, 14a–c, 15a–c, 16a–c, 17a–c, 18a–c, 19a–c, 20a–c, 21a–c, 22a–c, 23a–c, 24a–c, 25a–c, 26a–c, and 27a–c; saturation binding curves using [3H]CP-55,940 for CB1 and CB2 receptors pre-incubated with the 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c; and HPLC traces of 25a, 26c, 27b, and 31c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_001.pdf">PDF</a>).Molecular formula strings and biochemical data of 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of a pyrano[2,3-b]pyridine derivative YX-2102 as a cannabinoid receptor 2 agonist for alleviating lung fibrosis

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

The progress of small molecules against cannabinoid 2 receptor (CB2R)

A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for studies

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists

Large library docking for cannabinoid-1 receptor agonists with reduced side effects

Development of Yin-Yang ligand for cannabinoid receptors

Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists

In silico exploration of pyrocannabinoid interactions with key protein targets

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists

Highly Selective Drug-Derived Fluorescent Probes for the Cannabinoid Receptor Type 1 (CB1R)

Pyrazolidine-3,5-dione Derivatives As Potent Non-Steroidal Agonists of Farnesoid X Receptor: Virtual Screening, Synthesis, and Biological Evaluation.

Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects

Crystal Structure of the Human Cannabinoid Receptor CB2

Computational study of novel natural agonists targeting farnesoid X receptor